|
J Biol Chem, Vol. 274, Issue 45, 32234-32240, November 5, 1999
Microfibril-associated Protein 4 Is Present in Lung Washings and
Binds to the Collagen Region of Lung Surfactant Protein D*
Mette
Lausen ,
Nicholas
Lynch§,
Anders
Schlosser ,
Ida
Tornøe ,
Susanne Gjørup
Sækmose ,
Børge
Teisner ,
Antony C.
Willis¶,
Erika
Crouch ,
Wilhelm
Schwaeble§, and
Uffe
Holmskov **
From the Department of Immunology and Microbiology,
Institute of Medical Biology, University of Southern Denmark, Odense
University, DK-5000 Odense, Denmark, the § Department of
Microbiology and Immunology, University of Leicester, P. O. Box 138, University Road, Leicester LE1 9HN, United Kingdom, the
¶ Medical Research Council Immunochemistry Unit, Department of
Biochemistry, University of Oxford, South Parks Road, Oxford
OX1 3QU, United Kingdom, and the Department of Pathology,
Washington University, St. Louis, Missouri 63110
 |
ABSTRACT |
We have purified a glycoprotein from bovine lung
washings using affinity chromatography on a maltose-affinity column. On
SDS-polyacrylamide gel electrophoresis the protein showed a molecular
mass of 36 kDa in the reduced state and 66 kDa in the unreduced state.
On gel permeation chromatography the apparent molecular mass was 250 kDa. N-terminal sequencing showed homology to the human matrix protein
microfibril-associated protein (hMFAP4), and the glycoprotein was
designated bovine MFAP4 (bMFAP4). Lung surfactant protein D (SP-D) was
also purified from lung washings, and calcium-dependent binding was demonstrated between bMFAP4 and SP-D. hMFAP4 was cloned, and recombinant hMFAP4 showed the same binding pattern to SP-D as
bMFAP4. No binding was seen to recombinant SP-D composed of the neck
region and carbohydrate recognition domain of SP-D, indicating that the
interaction between MFAP4 and SP-D is mediated via the collagen region
of SP-D. MFAP4 also showed calcium-dependent binding to
mannan, which was partially inhibited by maltose. Our findings indicate
that MFAP4 has two binding specificities, one for collagen and one for
carbohydrate, and we suggest that MFAP4 may fix the collectins in the
extracellular compartment during inflammation.
 |
INTRODUCTION |
Lung surfactant protein D
(SP-D)1 belongs to a group of
proteins known as collectins (1, 2). These are C-type lectins containing collagen-like regions attached to carbohydrate recognition domains (CRDs) (3). SP-D is together with lung surfactant protein A
(SP-A) mainly found in the surfactant lining the alveolar epithelium, but both molecules are also produced by cells lining the
gastrointestinal tract (4, 5). Three serum collectins are known,
mannan-binding lectin, conglutinin, and collectin-43, which are all
produced by the liver (6, 7). The collectins are structurally related to C1q (8), a subcomponent of C1, and to the ficolins (9). The ficolins
differ from the collectins in having a C-terminal fibrinogen-like
domain attached to a collagen region. The fibrinogen-like domain of the
ficolins is responsible for the carbohydrate binding activity of the
ficolins and contains one potential calcium binding site (10-12).
The C-terminal CRDs of the collectins bind to carbohydrate ligands on
the surface of pathogens, whereas the collagen region interacts with
cell surface receptors to trigger phagocytosis or oxidative killing.
SP-A and SP-D also act as chemotactic agents for phagocytes, SP-D being
far more potent than SP-A (13-15), and both molecules bind directly to
alveolar macrophages in the absence of microbial ligands, thereby
mediating the generation of oxygen radicals (14, 16). Different
receptors have been described for both SP-A and SP-D (17-20), but it
is still not clear which receptors are responsible for the various
effector mechanisms elicited by SP-A and SP-D. The main role of SP-D
was long thought to be in innate defense against microorganisms, but
recent results with SP-D knock-out mice have shown that SP-D is more
involved in surfactant homeostasis than previously predicted (21,
22).
Here we describe the purification and characterization of a molecule
from bovine lung washings that binds calcium dependently to the
collagen regions of SP-D. This molecule also shows
calcium-dependent binding to mannan, which is partially
inhibited by maltose. The molecule was identified as the bovine
homologue to human microfibril-associated protein 4 (hMFAP4) and was
therefore designated bovine microfibril-associated protein 4 (bMFAP4).
hMFAP4 contains a fibrinogen-like region with high homology to the
fibrinogen-like region of the ficolins (23). The ligand motif
Arg-Gly-Asp for cell surface integrins is found in the N-terminal
region of MFAP4. MFAP4 is the second member of the fibrinogen domain
superfamily that shows lectin-like activity, and the possible roles of
this activity together with the collagen binding activity and the
potential integrin binding activity are discussed.
 |
EXPERIMENTAL PROCEDURES |
Buffers and Reagents--
Buffers and reagents used were
Tris-buffered saline (TBS): 140 mM NaCl, 10 mM
Tris-HCl, 0.02% (w/v) NaN3, pH 7.4; TBS/Tw: TBS containing
0.05% (v/v) Tween 20 (polyoxyethylenesorbitan monolaurate, Merck-Schuchardt, Germany); TBS/E: TBS containing 0.05% Emulphogene BC-720 (polyoxyethylene tridecyl ether, Sigma); phosphate-buffered saline: 137 mM NaCl, 3 mM KCl, 8 mM
Na2HPO4, 1.5 mM
KH2PO4, pH 7.4; coating buffer: 60 mM Na2CO3, 35 mM
NaHCO3, 0.02% (w/v) NaN3, pH 9.6; substrate
buffer: 100 mM Tris-HCl, 5 mM
MgCl2, 100 mM NaCl, pH 7.5. Rabbit anti-bovine
immunoglobulin antibody (Z247, Dako, Glostrup, Denmark) was coupled to
CNBr-activated-Sepharose 4B (Amersham Pharmacia Biotech) at a
concentration of 3.3 mg of antibody/ml of gel. Rabbit anti-chicken IgG
antibody (whole molecule) (C-2288, Sigma); alkaline
phosphatase-conjugated goat anti-rabbit IgG antibody (whole molecule)
(A-8025, Sigma); alkaline phosphatase-labeled avidin (A-2527, Sigma);
and p-nitrophenyl phosphate, disodium salt (Roche Molecular
Biochemicals) were used. Gelatin was from Difco (control 683467).
Bovine serum albumin was from Sigma (A-7638). Maltose-TSK gel was
prepared by coupling 100 mg of maltose/ml of divinylsulfone-activated
Fractogel TSK HW/75(F) (14985, Merck, Darmstadt, Germany) (24). Mannan
was prepared from Saccharomyces cerevisiae (25).
Purification of bMFAP4 and Bovine Lung SP-D--
Bovine lungs
were obtained from a local abattoir. The lungs were washed at 4 °C
with TBS containing enzyme inhibitors (5 mM iodoacetamide,
5 mM cyclocapron (trans-4-(aminomethyl)-cyclohexacarboxylic acid, Kabi Pharmacia, Sweden), 5 mM EDTA, 10 units/ml
Trasylol (aprotinin, Bayer, Leverkusen, Germany). The lung washings
(500 ml) were clarified by centrifugation at 1000 × g
for 15 min at 4 °C; then calcium was added to 25 mM, and
the pH was adjusted to 7.4. After another centrifugation (10,000 × g for 30 min) the supernatant was passed through a 50-ml
maltose-TSK column. The maltose-TSK column was washed extensively with
TBS/E containing enzyme inhibitors and 25 mM
CaCl2, and bound SP-D was eluted with TBS/E containing 5 mM CaCl2 and 100 mM maltose. After
another wash with TBS/E containing 5 mM CaCl2,
bound bMFAP4 was eluted with TBS/E containing 10 mM EDTA.
The eluate containing SP-D and the eluate containing bMFAP4 were passed
separately through a 10-ml rabbit anti-bovine Ig-Sepharose column to
remove anti-carbohydrate antibodies. Fractions of bMFAP4 were further
purified on a Superose 6 Prepgrade column (125 × 2.6 cm, Amersham
Pharmacia Biotech) at a flow rate of 30 ml/h.
The apparent molecular weight of bMFAP4 was estimated by gel permeation
chromatography on a Superose 12 column (30 × 1 cm, Amersham
Pharmacia Biotech) at a flow rate of 24 ml/h. The bMFAP4 sample was
concentrated using Centriprep concentrators (Amicon, Beverly, MA), and
a 200-µl sample containing approximately 25 µg/ml was then applied
to the column with TBS/E containing 10 mM EDTA as running
buffer. Blue dextran, fibronectin, and rabbit IgG were used to
calibrate the column.
The purification of bMFAP4 and SP-D was monitored by SDS-PAGE, and the
amount of protein in the fractions was estimated by their UV-absorption
at 280 nm on the assumption that E1 mg/ml at 280 nm was 1.0.
Expression of Recombinant Rat SP-D, Recombinant Rat SP-Dala72,
and Human SP-D Neck-CRD--
Recombinant rat SP-D (rrSP-D) and
recombinant rat SP-Dala72 (rrSP-Dala72) were expressed in Chinese
hamster ovary-K1 cells using the pEE14 transfection vector (26). Human
SP-D (hSP-D) neck-CRD was expressed using the pET32 expression system
(Novagen). Primers used for PCR amplification of the neck CRD were:
3'-CCGCGGATCCGGATTGAAGGGGG-5' (sense) and 3'-GGGAATTCCTCAGAACTCGCAGA-5'
(antisense) using a full-length cDNA as template. The PCR product
was inserted using the BamHI and EcoRI cloning
sites. Escherichia coli strain BL21-de3 was
transformed by electroporation, and the pET32-rSP-D construct was
sequenced before expression. Purification of the expressed protein was
performed on a nickel-nitrilotriacetic acid resin (Qiagen) followed by
enterokinase digestion to remove the thioredoxin tag. The neck-CRD was
finally subjected to maltose-agarose affinity chromatography.
cDNA Cloning and Expression of Human Recombinant MFAP4
(rhMFAP4)--
A full-length MFAP4 cDNA clone was isolated from a
human kidney cDNA library (CLONTECH Hl1123n),
subcloned into pBSKS+, and used as a template for PCR. A
pair of oligonucleotide primers was generated. The sense primer,
3'-GTCTAGAGGTCTCCGGGATCCGAG-5' corresponds to nucleotide 60-83 of the
MFAP4 cDNA containing a site for XbalI digestion, and
the antisense primer 3'-GTCGACCGGCGGATTTTCATCTC-5' corresponds to
nucleotide 749-771 of the cDNA sequence of MFAP4 containing a site
for SalI digestion. These were designed to allow in-frame
subcloning into pTrxFus (Invitrogen, Leek, The Netherlands). PCR
amplification was performed in a reaction volume of 50 µl containing
60 pmol of each primer, 10 nmol of dNTP, 20 ng of cDNA template,
and 2 units of Taq polymerase (Life Technologies, Inc.) in
the manufacturer's buffer. Thirty cycles of PCR amplification were
performed with a denaturing temperature at 94 °C for 45 s, annealing at 53 °C for 45 s, and allowing extension at 72 °C
for 1 min. The first denaturation cycle was prolonged to 2 min, and the
final extension cycle was prolonged to 5 min. The expected 714-base
pair PCR product was obtained and ligated into pCRII (Invitrogen BV).
Plasmid DNA was prepared, digested with XbalI and
SalI, and separated on an agarose gel. After
electrophoresis, the MFAP4 cDNA fragment was cut from the gel,
extracted with the Sephaglas Bandprep kit (Amersham Pharmacia Biotech),
and then ligated into pTrxFus (Invitrogen), which had previously been
digested with SalI and XbalI. The construct
(pSP-Etrx) was transformed into E. coli strain GI724, and
plasmid DNA was isolated and sequenced to confirm that the subcloning
had been successful.
A single colony carrying pSP-Etrx was inoculated into 3 ml of RMG-Amp
medium containing 1X M9 salts, 2% casamino acids, 0.5% glucose, 1 mM MgCl2, and 100 µg/ml ampicillin and grown
overnight at 30 °C. Fifty ml of induction medium (1X M9 salts, 0.2%
casamino acids, 0.5% glucose, 1 mM MgCl2, and
100 µg/ml ampicillin) were inoculated with 3 ml of culture and
incubated at 30 °C until the absorbance at 550 nm was ~0.5.
Protein expression was induced by adding 100 µg/ml L-tryptophan, and
the culture was allowed to grow for 4 h at 30 °C before the
cells were harvested by centrifugation. Cells expressing human kidney
rhMFAP4 were resuspended in 2.5 ml of TSB (50 mM NaCl, 100 mM Tris-HCl, 1 mM EDTA, 0.5% SDS, pH 7.0)
containing 0.1 M phenylmethylsulfonyl fluoride and lysed by
three cycles of sonication, rapid freezing, and thawing. Centrifugation of the sample at 12,000 × g gave a clear supernatant
containing 8 mg/ml soluble protein. Protein (20 mg) was applied to a
column of ThiobondTM resin (Invitrogen) and eluted with a gradient of 2-mercaptoethanol from 1 to 500 mM in TSB. Fractions were
examined for recombinant protein by SDS-PAGE.
As a control, the fusion partner, a 12-kDa thioredoxin peptide, was
expressed in E. coli using the plasmid pTrxFus. Thioredoxin control peptide was purified by osmotic shock according to the manufacturer's protocol (27).
Biotinylation--
Purified bMFAP4 and rhMFAP4 were labeled with
biotin (28). The proteins were dialyzed against phosphate-buffered
saline adjusted to pH 8.5 with 3% (w/v) Na2CO3
and biotin-N-hydroxysuccinimide ester (Sigma H-1759, 40 mg/ml in dimethyl sulfoxide) was added at 0.17 mg/mg protein. The
mixture was incubated for 4 h at room temperature and dialyzed
against TBS/E. The labeled bMFAP4 and rhMFAP4 were analyzed by SDS-PAGE
and Western blotting.
SDS-PAGE and Western Blotting--
Electrophoresis was performed
on 4-20% (w/v) polyacrylamide gradient gels in a discontinuous buffer
system (29). Samples were reduced by heating at 100 °C for 1 min in
60 mM dithiothreitol, 1.5% (w/v) SDS, 5% glycerol, 0.02%
bromphenol blue, 0.1 M Tris, pH 8.0, and alkylated by the
addition of iodoacetamide to a concentration of 140 mM.
Unreduced samples were heated for 1 min in sample buffer with 40 mM iodoacetamide followed by the addition of further
iodoacetamide to a concentration of 180 mM. Protein bands
were detected by silver staining (30).
Separated proteins were electroblotted (31) onto polyvinylidene
difluoride membranes (Immobilon-P, Bedford, MA) with 25% (v/v) ethanol
being substituted for methanol in the buffer. The paper was cut in 2-mm
strips and incubated with primary chicken antibodies overnight,
secondary rabbit anti-chicken antibodies for 1 h, and alkaline
phosphatase-coupled goat anti-rabbit IgG for 1 h. The antibodies
were diluted in high salt TBS (TBS containing 0.5 M NaCl
and 0.05% Tween). Control strips were incubated in high salt TBS or
normal chicken IgG purified from chicken egg yolk and diluted in high
salt TBS. When biotinylated bMFAP4 and biotinylated rhMFAP4 were
blotted, the strips were incubated with alkaline phosphatase-coupled
avidin for 1 h. The strips were washed and developed with nitro
blue tetrazolium and potassium-5-bromo-4-chloro-3-indolyl phosphate.
Molecular weight markers were Mark 12TM MW standards from Novex (San
Diego, CA). On the polyvinylidene difluoride membrane the markers were
stained with colloidal gold.
Collagenase Digestion and Deglycosylation of
bMFAP4--
Purified bMFAP4 and purified bovine SP-D were incubated
for 24 h at 37 °C with collagenase (1.25 units/100 µg of
protein) from Clostridium histolyticum (Sigma C-0773) in 25 mM Tris-HCl containing 10 mM CaCl2,
pH 7.4, or as control in 25 mM Tris-HCl containing 10 mM EDTA, pH 7.4. Samples were analyzed by SDS-PAGE.
N-linked saccharides in bMFAP4 were estimated by enzymatic
digestion with N-glycosidase F for 18 h at 37 °C
using the PGNase F kit (New England Biolabs, Beverly, MA). The product
was analyzed by Western blotting.
Preparation of Anti-bMFAP4 Antibodies--
Antibodies against
bMFAP4 were raised in chickens by subcutaneous immunization with an
emulsified mixture of equal volumes of bMFAP4 (19 µg) and Freund's
complete adjuvant (Statens Serum Institut, Copenhagen, Denmark). The
chickens were boosted 1 and 3 months after the initial immunization
with the same amount of antigen in Freund's complete adjuvant.
Purification of IgG from Chicken Egg Yolk--
Egg yolk (15 ml)
was suspended in 15 ml of TBS and 60 ml of 0.06 M sodium
acetate buffer, pH 4.0, after which 2 ml of caprylic acid (Statens
Serum Institut) were added. After stirring for 30 min at room
temperature the mixture was centrifuged (10,000 × g
for 25 min at 4 °C), and the pellet and floating lipid fraction were
discarded. The supernatant was adjusted to pH 7.0 and cleared by
filtration. IgG was precipitated by adding polyethylene glycol 6000 (Merck-Schuchardt) to a final concentration of 9% (w/v). After
stirring for 30 min at 4 °C the mixture was centrifuged (10,000 × g for 25 min at 4 °C), and the pellet dissolved in
TBS. Normal chicken IgG was purified from nonimmune chicken egg yolk.
Enzyme-linked Binding Assay--
Microtiter plates (Polysorp,
Nalge-Nunc International, Kamstrup, Denmark) were coated with purified
SP-D, recombinant rat SP-D, SP-Dala72, neck-CRD SP-D, gelatin, bovine
serum albumin, or mannan (1 µg/ml in coating buffer) for 2 h at
room temperature. When collagenase-digested SP-D was used, the plates
were coated with 10 µg of protein/ml. All incubations were carried
out in a volume of 100 µl/well at room temperature in a moist
chamber. The plates were washed three times with TBS/Tw and blocked
with TBS/Tw containing either 5 mM CaCl2 or 10 mM EDTA for 30 min. The plates were then incubated
overnight with dilutions of biotinylated bMFAP4 or biotinylated rhMFAP4
in TBS/Tw containing 0.1% bovine serum albumin and either 5 mM CaCl2 or 10 mM EDTA. This and
the following steps were carried out on a shaking platform. Between all
the following steps the plates were washed three times in TBS/Tw
containing either 5 mM CaCl2 or 10 mM EDTA. In the inhibition assay the binding of
biotinylated bMFAP4 to SP-D was inhibited by unlabeled bMFAP4 at
various concentrations in the presence of 5 mM
CaCl2. After washing, the plates were incubated with
alkaline phosphatase-coupled avidin diluted 1/1000 in TBS/Tw buffer
containing either 5 mM CaCl2 or 10 mM EDTA. After a final wash, the bound enzyme was estimated
by adding p-nitrophenylphosphate, disodium salt at 1 mg/ml
in substrate buffer. The absorbance of the wells was read at 405 nm by
means of a multichannel spectrophotometer (EAR 400 FT;
SLT-Labinstruments, Innsbruck, Austria).
Amino Acid Sequencing and Amino Acid Analysis--
The
procedures were as described (32). Amino acid analysis was performed
directly on purified bMFAP4 in an Applied Biosystems 420A amino acid
analyzer (Perkin-Elmer, Applied Biosystems Division). For N-terminal
and peptide sequencing, purified bMFAP4 was run on SDS-PAGE and
electroblotted onto polyvinylidene difluoride membranes prior to
detection with Ponceau-S dye. The bMFAP4 band was excised from the blot
and sequenced or digested with trypsin (modified trypsin sequencing
grade, Promega, United Kingdom) for 16 h at 37 °C. The
supernatants were then subjected to reverse phase chromatography on a
Brownlee BU-300 VC4 column (100 × 1 mm). Peaks were collected and
sequenced in an Applied Biosystems 470A protein sequencer (Perkin
Elmer). Sequences similar to bMFAP4 were searched for in
GenBank/EBI/DDBI/PDB data bases using the BLAST program. Alignment of
multiple sequences was carried out by the Clustal method using the
PAM250 residue weight table.
 |
RESULTS |
Identification and Purification of bMFAP4--
During the
purification of bovine SP-D a molecule with a molecular mass of 36 kDa
was observed on SDS-PAGE in the reduced state. This molecule was
subsequently identified by N-terminal sequencing as the homolog of
bMFAP4. The 10,000 × g supernatant from bovine lung
washings was applied to a maltose-TSK column in the presence of 5 mM CaCl2, and after eluting SP-D with 100 mM maltose, bMFAP4 was eluted with 10 mM EDTA.
Bovine MFAP4 and SP-D were cleared of anti-carbohydrate antibodies on a
rabbit anti-bovine Ig-Sepharose column. In some purifications a
proportion of bMFAP4 was eluted together with SP-D in the maltose
eluate. Fig. 1 shows SDS-PAGE analysis of
purified bMFAP4 in the reduced (lane 1) and unreduced
(lane 2) state. Reduced bMFAP4 migrates as a major band of
36 kDa and a minor band of 70 kDa, whereas unreduced bMFAP4 migrates as
a single band of 66 kDa. Purified bMFAP4 was analyzed by gel permeation
chromatography on Superose 12 and showed an apparent molecular mass of
250 kDa when globular proteins were used as markers (Fig.
2). Approximately 800 µg of bMFAP4
(estimated by E280) was obtained from 1 liter of
lung washings.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 1.
SDS-PAGE of purified bMFAP4.
Lanes 1 and 2 show bMFAP4 in the reduced
and unreduced state, respectively, on a 4-20% (w/v) gradient gel.
Protein bands were silver-stained.
|
|

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 2.
Gel permeation chromatography of purified
bMFAP4 on a Superose 12 column (30 × 1 cm). The column was
calibrated with blue dextran (V0), purified
fibronectin (FN) (440 kDa), and normal rabbit IgG (150 kDa).
|
|
Deglycosylation of bMFAP4--
N-linked glycosylation
was estimated by means of N-glycosidase F digestion, and the
product was analyzed by SDS-PAGE and Western blotting. Western blotting
was necessary because of the identical molecular mass of
N-glycosidase F and deglycosylated bMFAP4. Fig. 3A shows bMFAP4 in the reduced
state before (lane 1) and after (lane 2)
treatment with N-glycosidase F. The molecular mass of bMFAP4 is reduced from 36 to 33 kDa upon deglycosylation. The specificity of the polyclonal anti-bMFAP4 chicken antibodies was analyzed by Western blotting of crude bovine lung washings containing bMFAP4 in the reduced state (Fig. 3B). A major specific band
is seen at a position corresponding to a molecular mass of 36 kDa (lane 2).

View larger version (63K):
[in this window]
[in a new window]
|
Fig. 3.
. Deglycosylation of bMFAP4. A,
Western blot of bMFAP4 untreated (lane 1) or treated with
N-glycosidase F (lane 2). The strips were
developed with chicken anti-bMFAP4. B, specificity of the
chicken anti-bMFAP4 antibody. Western blots of bovine lung washings
with bMFAP4 in the reduced state. The strips were incubated with normal
chicken IgG (lane 1) or anti-bMFAP4 (lane 2), and
bound antibody was visualized by means of secondary rabbit anti-chicken
antibodies and alkaline phosphatase-coupled goat anti-rabbit IgG and
substrate. Lane 3 was stained with colloidial gold.
|
|
Amino Acid Sequencing and Amino Acid Analysis--
The N-terminal
amino acid sequence and amino acid sequences of different proteolytic
fragments obtained by tryptic digestion of bMFAP4 are shown in Fig.
4, A and B.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 4.
A, the N-terminal amino acid sequence of
bMFAP4 as determined by protein sequencing compared with N terminus
sequences of hMFAP4 (23), porcine MAP (pMAP) (33), and
bovine MAP (bMAP) (34). B, amino acid sequences
of fragments obtained by tryptic digestion of bMFAP4. C,
comparison of amino acid sequences of hMFAP4 with the sequence of human
fibrinogen chain (35) and the fibrinogen domains of P35 (10) and
human ficolin (36). Identical amino acids are marked in
yellow, cysteines are marked in red, and the RGD
motif is in green. The potential calcium binding site
deduced by terbium fluorescence studies is indicated by a dotted
line, and the residues involved in calcium binding, as deduced
from the crystal structure of the fibrinogen chain, are shown in
open boxes. The potential integrin binding site is indicated
with a bold dashed line. Gaps in the alignment are shown by
a light dash.
|
|
The N terminus of bMFAP4 showed homology to a 36-kDa
microfibril-associated protein (MAP) found in bovine (34) and porcine aorta (33) and to human MFAP4 (23). An Arg-Gly-Asp (RGD) sequence is
conserved in the N termini of these proteins. This sequence motif is
often associated with cell adhesive activity and is the ligand motif
for cell surface integrins (37, 38).
cDNA Cloning and Expression of rhMFAP4--
A full-length
cDNA clone of MFAP4 was obtained from a human cDNA kidney
library and showed 99.8% identity with the published sequence (23)
with a single base shift (A to G) changing the amino acid at position
124 from an Asp to a Gly. The coding region spanned 255 amino acids
with an N-terminal region of 16 amino acids containing an Arg-Gly-Asp
sequence and one cysteine residue. The N-terminal region was followed
by a single fibrinogen-like domain of 239 amino acids showing high
homology to fibrinogen domains found in human ficolin (36) and P35 (10)
(Fig. 4C). A potential calcium binding site is marked with a
dotted line (39, 40). An internal peptide motif found in the
chain of fibrinogen mediating the interaction of fibrinogen with
the leukocyte integrin Mac-1 (41, 42) is marked with a bold
dashed line.
The cDNA of hMFAP4 was transformed into the E. coli
strain G1724 by means of the plasmid pTrxFus where it was expressed as a thioredoxin fusion protein. After induction of protein expression the
cells were lysed, and the fusion protein was purified. Fig. 5 shows the SDS-PAGE analysis of the
elution profile from the ThiobondTM resin affinity column. Human
recombinant MFAP4 migrates as a molecule of 45 kDa in the reduced
state, and unreduced rhMFAP4 shows the same mobility (data not shown),
indicating that the recombinant molecule fails to form disulfide
bondings.

View larger version (119K):
[in this window]
[in a new window]
|
Fig. 5.
SDS-PAGE of the elution profile from the
ThiobondTM resin column. Lanes 1-4, elution with 1, 5, 20, and 100 mM 2-mercaptoethanol, respectively.
|
|
Binding Specificity--
In the presence of 5 mM
CaCl2, rhMFAP4 and bMFAP4 bound to microtiter plates
coated with bovine SP-D (Fig. 6). The
binding was concentration-dependent and inhibited by 10 mM EDTA. No binding of bMFAP4 was seen if SP-D was digested
with collagenase, indicating that bMFAP4 binds to the collagen region
of SP-D (Fig. 7A). Purified SP-D is shown in Fig. 7C, lane 1, and
collagenase-treated SP-D is shown in lane 2. The 43-kDa band
seen in lane 1 has disappeared and a 20-kDa band
corresponding to the neck-CRD region of SP-D has appeared. The
additional bands seen from 60 to 100 kDa originate from the collagenase
preparation. bMFAP4 and rhMFAP4 also showed calcium-dependent binding to gelatin supporting the idea
that MFAP4 binds to the collagen region of SP-D (Fig.
7B).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 6.
. Calcium-dependent binding of
MFAP4 to SP-D. Microtiter plates were coated with bovine SP-D, and
serial dilutions of biotinylated bMFAP4 (solid line) or
rhMFAP4 (dashed line) were added to the wells in the
presence of 5 mM CaCl2 ( ) or 10 mM EDTA ( ).
|
|

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 7.
Binding of MFAP4 to collagen.
A, microtiter plates were coated with bovine SP-D ( ) or
collagenase-digested bovine SP-D ( ). Serial dilutions of
biotinylated bMFAP4 were added to the wells in the presence of 5 mM CaCl2. B, microtiter plates were
coated with gelatin, and serial dilutions of biotinylated bMFAP4
(solid line) or rhMFAP4 (dashed line) were added
to the wells in the presence of 5 mM CaCl2
( ) or 10 mM EDTA ( ). C, SDS-PAGE of
reduced SP-D before (lane 1) and after (lane 2)
collagenase treatment.
|
|
rhMFAP4 bound equally well to rrSP-D and rrSP-Dala72 in a
dose-dependent manner, whereas no binding was seen to hSP-D
neck-CRD (Fig. 8). In the same experiment
no binding was seen to bovine serum albumin. The binding between MFAP4
and solid-phase SP-D was not inhibited by SP-D in solution at a
concentration of 25 µg/ml (data not shown).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 8.
Binding of MFAP4 to recombinant SP-D.
Microtiter plates were coated with recombinant rSP-D ( ), rrSP-Dala72
( ), hSP-D neck CRD ( ), or bovine serum albumin ( ). Serial
dilutions of biotinylated rhMFAP4 were added to the wells in the
presence of 5 mM CaCl2.
|
|
Fig. 9 shows that bMFAP4 and rhMFAP4 also
bound to microtiter plates coated with mannan. This binding was
concentration- and calcium-dependent and took place at
physiological ionic strength. The binding was partially inhibited by
100 mM maltose.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 9.
Binding of MFAP4 to mannan.
A, serial dilutions of biotinylated bMFAP4 were added to
mannan-coated wells in the presence of 5 mM
CaCl2 ( ), 5 mM CaCl2 containing
100 mM maltose ( ), or 10 mM EDTA ( ).
B, serial dilutions of biotinylated rhMFAP4 were added to
the mannan-coated wells in the presence of 5 mM
CaCl2 ( ), 5 mM CaCl2 containing
100 mM maltose ( ), or 10 mM EDTA
( ).
|
|
The binding of biotinylated bMFAP4 or rhMFAP4 to SP-D could be
inhibited by unlabeled bMFAP4 or rhMFAP4, respectively, demonstrating that the biotinylation had not radically altered the binding properties of bMFAP4 or rhMFAP4 (data not shown).
 |
DISCUSSION |
The present report describes the identification, purification, and
characterization of an SP-D-binding molecule from bovine lung washings.
The protein was identified as the bovine homolog of human MFAP4 and was
termed bMFAP4. Human recombinant MFAP4 and bMFAP4 showed
calcium-dependent binding to the collagen structure of SP-D
and to mannan.
On SDS-PAGE bMFAP4 showed a molecular mass of 36 kDa in the reduced
state and 66 kDa in the unreduced state. A minor band at 70 kDa seen on
SDS-PAGE in the reduced state was probably because of incomplete
disruption of an interchain disulfide bond. This band pattern has also
been observed for the homologue porcine protein 36-kDa MAP (33). The
apparent molecular mass of native bMFAP4 was estimated as 250 kDa on
gel permeation chromatography. N-linked glycosylation was
demonstrated by digestion with N-glycosidase F, which
reduced the molecular mass to 33 kDa. These data suggest that bMFAP4 is
a disulfide-linked homodimeric glycoprotein with a molecular mass of 66 kDa, organized into a higher oligomeric form via noncovalent interactions.
The N-terminal amino acid sequence of bMFAP4 showed a high degree of
homology with hMFAP4 with 10 of 14 amino acid residues being conserved,
including the RGD motif and the cysteine at position 10 (23). The
N-terminal amino acid sequence also showed homology with the
microfibril-associated glycoproteins (36-kDa MAP) found in the bovine
and porcine aorta. On SDS-PAGE the migration pattern of reduced and
unreduced bovine 36-kDa MAP was similar to the migration pattern of
reduced and unreduced bMFAP4 (34), but the N-terminal amino acid
sequence of 36-kDa MAP deviated at one position from bMFAP4. Possibly
two closely related forms of bMFAP4 exist.
The short peptide sequence RGD is conserved in the 36-kDa aorta MAP,
hMFAP4, and bMFAP4. This sequence was initially seen in fibronectin
(37) and is the ligand motif for cell surface integrins. The RGD motif
is found in many other proteins involved in cell adhesive activity
(38). These include the tenascins, which form a family of large and
complex extracellular matrix proteins (43). They are believed to be
involved in processes of tissue formation and remodeling. The tenascins
also contain a C-terminal fibrinogen-like domain, which in human (44)
and porcine tenascins (45) shows a 52-54% sequence identity to hMFAP4 (23). The cell adhesive activity of the tenascins has also been located
to the C-terminal fibrinogen-like domain (46). An internal peptide
sequence from the fibrinogen chain (GWTVFQKRLDGSV) has been shown
to be involved in binding to the leukocyte integrin Mac-1 (41). This
peptide sequence is highly conserved between the fibrinogen chain
and hMFAP4. Thus two potential cell adhesive motifs are found in hMFAP4.
The fibrinogen-like domain of hMFAP4 reveals a 48-50% sequence
identity to the fibrinogen-like domains of the human ficolins. Two
types of ficolin are found in man; P35 or L-ficolin is a
plasma protein synthesized by the liver, and M-ficolin is mainly
synthesized by monocytes and can be detected on the monocyte surface.
The ficolins are composed of collagen-like regions attached to
fibrinogen-like domains. Via its fibrinogen-like domain, P35 can bind
to the glycosylated surfaces of pathogens and enhance phagocytosis of
these pathogens by neutrophils, and P35 also interacts in a
calcium-dependent manner with mannan (10). Terbium
fluorescence studies localized a calcium binding site on the human
fibrinogen chain, which corresponds to residues 162-187 in hMFAP4
(40), and the crystal structure of the human fibrinogen domain
revealed a short calcium-binding loop in the same region with the four
residues Asp-171, Asp-173, Phe-175, and Gly-177 as ligands for the
calcium ion (39). Asp-171 and Asp-173 are highly conserved in all
fibrinogen domains, whereas the residues at positions 175 and 177 vary
considerably. Three of the four calcium ligand residues are conserved
in hMFAP4, Gly-177 being substituted by Gln in hMFAP4. Calcium binding
site 2 of the C-type lectin CRD is the center of
calcium-dependent carbohydrate recognition. Five residues
are responsible for this interaction, three of which are highly
conserved in all C-type CRDs, whereas the remaining two vary and
determine the carbohydrate specificity of the C-type lectin (47).
Although the structure of the calcium-binding loop of fibrinogen
differs considerably from that of the C-type CRD, it is tempting to
speculate that residues 175 and 177 might determine the
calcium-dependent ligand specificity of the fibrinogen domain.
Both bMFAP4 and rhMFAP4 bind in a calcium-dependent manner
to SP-D at physiological ionic strength. bMFAP4 does not interact with
collagenase-digested bSP-D, and rhMFAP4 does not interact with a
recombinant form of human SP-D lacking the collagen domain. These
results indicate that the interaction is mediated by the collagen
region of SP-D and this is further supported by the finding that both
bMFAP4 and rhMFAP4 bind calcium dependently to collagen in the form of
gelatin. The binding between MFAP4 and solid-phase SP-D was not
inhibited by SP-D in solution at a concentration of 25 µg/ml (data
not shown). This could mean that conformational changes induced by
partial denaturation of the collagen region of SP-D are needed before
binding between SP-D and MFAP4 can take place. Such conformational
changes may take place during inflammation.
Both rhMFAP4 and bMFAP4 bind to mannan. This interaction is partly
inhibited by maltose and totally inhibited by EDTA. Bovine MFAP4 bound
to the maltose-TSK column in the presence of calcium, but only trace
amounts of bMFAP4 were eluted with 100 mM maltose, whereas
the rest was subsequently eluted with EDTA. In fact bMFAP4 also bound
to a nonderivatized TSK column (data not shown), suggesting that other
forces than the lectin-carbohydrate interaction are involved in the
calcium-dependent binding of bMFAP4 to the maltose-TSK column.
The lectin activity of MFAP4 raised the possibility that the
interaction takes place via the N-linked carbohydrate
located in the collagen region of SP-D at position Asn-70. We therefore compared the binding between rhMFAP4 and rrSP-Dala72 and wild-type rrSP-D. rrSP-Dala72 has substituted a Ser to Ala at residue 72 of SP-D,
altering the N-linked glycosylation recognition site. The
two forms of rat SP-D bound equally well to rhMFAP4, and therefore the
N-linked carbohydrate does not influence the interaction
between SP-D and MFAP4.
Bovine and porcine MAP were earlier described as extracellular matrix
proteins purified from aortic tissue (33, 34). The role played by these
proteins in the extracellular matrix is unknown, but porcine 36-kDa MAP
colocalizes with elastin microfibrils in the aorta (33). In humans,
deletions of the MFAP4 gene have been correlated with Smith-Magenis
syndrome, which is characterized by multiple congenital anomalities and
mental retardation. We have now shown that bMFAP4 is present in lung
washings as a soluble protein. Other extracellular matrix proteins,
such as fibronectin and fibulin, are also known to be present both in
the extracellular matrix and in various body fluids.
The properties of MFAP4 show that it has the potential of participating
in the complex interactions of inflammatory processes, involving the
adhesion of leukocytes via integrin receptors and the binding of SP-D
via the collagen regions. SP-D can subsequently bind receptors on the
phagocytes, and this binding may lead to activation of the respiratory
burst (14, 16) or the secretion of proinflammatory cytokines (48, 49)
as well as to further differentiation of the phagocytes (50). Finally,
MFAP4 has the potential of opsonizing microorganisms on its own through
binding to microbial surface carbohydrates.
Further studies are needed to locate the binding sites for collagen and
carbohydrate on MFAP4 and to define MFAP4 as a integrin-binding molecule. This information could lead to a better understanding of how
the interactions between collectins, macrophages, and MFAP4, located in
solution as well as in the extracellular matrix, are orchestrated
during inflammation.
 |
FOOTNOTES |
*
This work was supported by Danish Medical Research Council
Grants 96-0160-2 and 97-0055-8, The Arthritis Research Campaign, UK,
The Benzon Foundation, The Michaelsen Foundation, and the Novo Nordisk
Foundation.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
To whom correspondence should be addressed. Tel.: +45 65 50 37 75;
Fax: +45 65 91 52 67; E-mail: holmskov@imbmed.sdu.dk.
 |
ABBREVIATIONS |
The abbreviations used are:
SP-D, surfactant
protein D;
CRD, carbohydrate recognition domain;
SP-A, surfactant
protein A;
MFAP4, microfibril-associated protein 4;
h, human;
b, bovine;
rr, recombinant rat;
rh, recombinant human;
TBS, Tris-buffered
saline;
PAGE, polyacrylamide gel electrophoresis;
PCR, polymerase chain
reaction;
MAP, microfibril-associated protein.
 |
REFERENCES |
| 1.
|
Eggleton, P.,
and Reid, K. B.
(1999)
Curr. Opin. Immunol.
11,
28-33[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Crouch, E. C.
(1998)
Biochim. Biophys. Acta
1408,
278-289[Medline]
[Order article via Infotrieve]
|
| 3.
|
Hansen, S.,
and Holmskov, U.
(1998)
Immunobiology
199,
165-189[Medline]
[Order article via Infotrieve]
|
| 4.
|
Fisher, J. H.,
and Mason, R.
(1995)
Am. J Respir. Cell Mol. Biol.
12,
13-18[Abstract]
|
| 5.
|
Rubio, S.,
Lacaze-Masmonteil, T.,
Chailley-Heu, B.,
Kahn, A.,
Bourbon, J. R.,
and Ducroc, R.
(1995)
J. Biol. Chem.
270,
12162-12169[Abstract/Free Full Text]
|
| 6.
|
Holmskov, U.,
and Jensenius, J. C.
(1996)
in
Collectins and Innate Immunity
(Ezekowitz, R. A. B.
, Sastry, K.
, and Reid, K. B. M., eds)
, pp. 51-71, R. G. Landers Company, Austin, TX
|
| 7.
|
Turner, M. W.
(1996)
Immunol. Today
17,
532-540[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Reid, K. B. M.
(1996)
in
Collectins and Innate Immunity
(Ezekowitz, R. A. B.
, Salstry, K.
, and Reid, K. B. M., eds)
, pp. 99-111, R. G. Landers Company, Austin, TX
|
| 9.
|
Lu, J.,
and Le, Y.
(1998)
Immunobiology
199,
190-199[Medline]
[Order article via Infotrieve]
|
| 10.
|
Matsushita, M.,
Endo, Y.,
Taira, S.,
Sato, Y.,
Fujita, T.,
Ichikawa, N.,
Nakata, M.,
and Mizuochi, T.
(1996)
J. Biol. Chem.
271,
2448-2454[Abstract/Free Full Text]
|
| 11.
|
Ohashi, T.,
and Erickson, H. P.
(1997)
J. Biol. Chem.
272,
14220-14226[Abstract/Free Full Text]
|
| 12.
|
Le, Y.,
Lee, S. H.,
Kon, O. L.,
and Lu, J.
(1998)
FEBS Lett.
425,
367-370[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Crouch, E. C.,
Persson, A.,
Griffin, G. L.,
Chang, D.,
and Senior, R. M.
(1995)
Am. J. Respir. Cell Mol. Biol.
12,
410-415[Abstract]
|
| 14.
|
van Iwaarden, F.,
Welmers, B.,
Verhoef, J.,
Haagsman, H. P.,
and van Golde, L. M.
(1990)
Am. J. Respir. Cell Mol. Biol.
2,
91-98
|
| 15.
|
Cai, G. Z.,
Griffin, G. L.,
Senior, R. M.,
Longmore, W. J.,
and Moxley, M. A.
(1999)
Am. J. Physiol.
276,
L131-L136[Abstract/Free Full Text]
|
| 16.
|
van Iwaarden, J. F.,
Shimizu, H.,
Van Golde, P. H.,
Voelker, D. R.,
and van Golde, L. M.
(1992)
Biochem. J.
286,
5-8
|
| 17.
|
Nepomuceno, R. R.,
Henschen-Edman, A. H.,
Burgess, W. H.,
and Tenner, A. J.
(1997)
Immunity
6,
119-129[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Holmskov, U.,
Lawson, P.,
Teisner, B.,
Tornoe, I.,
Willis, A. C.,
Morgan, C.,
Koch, C.,
and Reid, K. B.
(1997)
J. Biol. Chem.
272,
13743-13749[Abstract/Free Full Text]
|
| 19.
|
Malhotra, R.,
Thiel, S.,
Reid, K. B.,
and Sim, R. B.
(1990)
J. Exp. Med.
172,
955-959[Abstract/Free Full Text]
|
| 20.
|
Chroneos, Z. C.,
Abdolrasulnia, R.,
Whitsett, J. A.,
Rice, W. R.,
and Shepherd, V. L.
(1996)
J. Biol. Chem.
271,
16375-16383[Abstract/Free Full Text]
|
| 21.
|
Korfhagen, T. R.,
Sheftelyevich, V.,
Burhans, M. S.,
Bruno, M. D.,
Ross, G. F.,
Wert, S. E.,
Stahlman, M. T.,
Jobe, A. H.,
Ikegami, M.,
Whitsett, J. A.,
and Fisher, J. H.
(1998)
J. Biol. Chem.
273,
28438-28443[Abstract/Free Full Text]
|
| 22.
|
Botas, C.,
Poulain, F.,
Akiyama, J.,
Brown, C.,
Allen, L.,
Goerke, J.,
Clements, J.,
Carlson, E.,
Gillespie, A. M.,
Epstein, C.,
and Hawgood, S.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
11869-11874[Abstract/Free Full Text]
|
| 23.
|
Zhao, Z.,
Lee, C. C.,
Jiralerspong, S.,
Juyal, R. C.,
Lu, F.,
Baldini, A.,
Greenberg, F.,
Caskey, C. T.,
and Patel, P. I.
(1995)
Hum. Mol. Genet.
4,
589-597[Abstract/Free Full Text]
|
| 24.
|
Fornstedt, N.,
and Porath, J.
(1975)
FEBS Lett.
57,
187-191[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Nakajima, T.,
and Ballou, C. E.
(1974)
J. Biol. Chem.
249,
7679-7684[Abstract/Free Full Text]
|
| 26.
|
Brown-Augsburger, P.,
Chang, D.,
Rust, K.,
and Crouch, E. C.
(1996)
J. Biol. Chem.
271,
18912-18919[Abstract/Free Full Text]
|
| 27.
|
Lunn, C. A.,
and Pigiet, V. P.
(1982)
J. Biol. Chem.
257,
11424-11430[Free Full Text]
|
| 28.
|
Guesdon, J. L.,
Ternynck, T.,
and Avrameas, S.
(1979)
J. Histochem. Cytochem.
27,
1131-1139[Abstract]
|
| 29.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Nesterenko, M. V.,
Tilley, M.,
and Upton, S. J.
(1994)
J. Biochem. Biophys. Methods
28,
239-242[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Towbin, H.,
Staehelin, T.,
and Gordon, J.
(1979)
Proc. Natl. Acad. Sci. U. S. A.
76,
4350-4354[Abstract/Free Full Text]
|
| 32.
|
Crawford, C.,
Brown, N. R.,
and Willis, A. C.
(1990)
Biochem. J.
265,
575-579[Medline]
[Order article via Infotrieve]
|
| 33.
|
Kobayashi, R.,
Tashima, Y.,
Masuda, H.,
Shozawa, T.,
Numata, Y.,
Miyauchi, K.,
and Hayakawa, T.
(1989)
J. Biol. Chem.
264,
17437-17444[Abstract/Free Full Text]
|
| 34.
|
Kobayashi, R.,
Mizutani, A.,
and Hidaka, H.
(1994)
Biochem. Biophys. Res. Commun.
198,
1262-1266[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Henschen, A.,
Lottspeich, F.,
Topfer Petersen, E.,
and Warbinek, R.
(1979)
Thromb. Haemostasis
41,
662-670[Medline]
[Order article via Infotrieve]
|
| 36.
|
Lu, J.,
Tay, P. N.,
Kon, O. L.,
and Reid, K. B.
(1996)
Biochem. J.
313,
473-478
|
| 37.
|
Pierschbacher, M. D.,
and Ruoslahti, E.
(1984)
Nature
309,
30-33[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Hynes, R. O.
(1992)
Cell
69,
11-25[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Yee, V. C.,
Pratt, K. P.,
Cote, H. C.,
Trong, I. L.,
Chung, D. W.,
Davie, E. W.,
Stenkamp, R. E.,
and Teller, D. C.
(1997)
Structure
5,
125-138[Medline]
[Order article via Infotrieve]
|
| 40.
|
Dang, C. V.,
Ebert, R. F.,
and Bell, W. R.
(1985)
J. Biol. Chem.
260,
9713-9719[Abstract/Free Full Text]
|
| 41.
|
Altieri, D. C.,
Agbanyo, F. R.,
Plescia, J.,
Ginsberg, M. H.,
Edgington, T. S.,
and Plow, E. F.
(1990)
J. Biol. Chem.
265,
12119-12122[Abstract/Free Full Text]
|
| 42.
|
Altieri, D. C.,
Plescia, J.,
and Plow, E. F.
(1993)
J. Biol. Chem.
268,
1847-1853[Abstract/Free Full Text]
|
| 43.
|
Erickson, H. P.
(1993)
Curr. Opin. Cell Biol.
5,
869-876[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Bristow, J.,
Tee, M. K.,
Gitelman, S. E.,
Mellon, S. H.,
and Miller, W. L.
(1993)
J. Cell Biol.
122,
265-278[Abstract/Free Full Text]
|
| 45.
|
Nishi, T.,
Weinstein, J.,
Gillespie, W. M.,
and Paulson, J. C.
(1991)
Eur. J. Biochem.
202,
643-648[Medline]
[Order article via Infotrieve]
|
| 46.
|
Clark, R. A.,
Erickson, H. P.,
and Springer, T. A.
(1997)
J. Cell Biol.
137,
755-765[Abstract/Free Full Text]
|
| 47.
|
Weis, W. I.,
Drickamer, K.,
and Hendrickson, W. A.
(1992)
Nature
360,
127-134[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Kremlev, S. G.,
and Phelps, D. S.
(1994)
Am. J. Physiol.
267,
L712-L719[Abstract/Free Full Text]
|
| 49.
|
Kremlev, S. G.,
Umstead, T. M.,
and Phelps, D. S.
(1997)
Am. J. Physiol.
272,
L996-L1004[Abstract/Free Full Text]
|
| 50.
|
Kremlev, S. G.,
and Phelps, D. S.
(1997)
Am. J. Physiol.
272,
L1070-L1077[Abstract/Free Full Text]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. L. Hartshorn, M. R. White, T. Tecle, U. Holmskov, and E. C. Crouch
Innate Defense against Influenza A Virus: Activity of Human Neutrophil Defensins and Interactions of Defensins with Surfactant Protein D.
J. Immunol.,
June 1, 2006;
176(11):
6962 - 6972.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Leth-Larsen, C. Floridon, O. Nielsen, and U. Holmskov
Surfactant protein D in the female genital tract
Mol. Hum. Reprod.,
March 1, 2004;
10(3):
149 - 154.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. L. Hartshorn, M. R. White, T. Mogues, T. Ligtenberg, E. Crouch, and U. Holmskov
Lung and salivary scavenger receptor glycoprotein-340 contribute to the host defense against influenza A viruses
Am J Physiol Lung Cell Mol Physiol,
November 1, 2003;
285(5):
L1066 - L1076.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Nadesalingam, A. L. Bernal, A. W. Dodds, A. C. Willis, D. J. Mahoney, A. J. Day, K. B. M. Reid, and N. Palaniyar
Identification and Characterization of a Novel Interaction between Pulmonary Surfactant Protein D and Decorin
J. Biol. Chem.,
July 3, 2003;
278(28):
25678 - 25687.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Kielty, M. J. Sherratt, and C. A. Shuttleworth
Elastic fibres
J. Cell Sci.,
July 15, 2002;
115(14):
2817 - 2828.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|